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Bartter syndrome is a hereditary disorder that has been characterized by the association of hypokalemia, alkalosis, and the
hypertrophy of the juxtaglomerular complex with secondary hyperaldosteronism and normal blood pressure. By contrast, the
genetic causes of Bartter syndrome primarily aﬀect molecular structures directly involved in the sodium reabsorption at the
level of the Henle loop. The ensuing urinary sodium wasting and chronic sodium depletion are responsible for the contraction
of the extracellular volume, the activation of the renin-aldosterone axis, the secretion of prostaglandins, and the biological
adaptations of downstream tubular segments, meaning the distal convoluted tubule and the collecting duct. These secondary
biological adaptations lead to hypokalemia and alkalosis, illustrating a close integration of the solutes regulation in the tubular
structures.
1.Introduction
Bartter syndrome is a hereditary disorder that has been char-
acterizedbytheassociationofhypokalemia,alkalosisandthe
hypertrophy of the juxtaglomerular complex with secondary
hyperaldosteronism and normal blood pressure [1]. By
contrast, the genetic causes of Bartter syndrome primarily
aﬀect molecular structures directly involved in the sodium
reabsorptionattheleveloftheHenleloop(seethefunctional
segmentation of sodium reabsorption in Figure 1 and [2, 3].
The ensuing urinary sodium wasting and chronic sodium
depletion are responsible for the contraction of the extracel-
lularvolume,theactivationoftherenin-aldosterone axis,the
secretion of prostaglandins, and the biological adaptations
of downstream tubular segments, meaning the distal convo-
lutedtubuleandthecollectingduct.Thesesecondarybiolog-
ical adaptations lead to hypokalemia and alkalosis, illustrat-
ing a close integration of the solutes regulation in the tubular
structures.
2.PrimaryMolecular Defects
andDirectConsequences
Genome alterations leading to the Bartter syndrome aﬀect
the genes encoding diﬀerent molecules involved in the
sodium reabsorption at the level of the large ascending limb
of the Henle loop (Figure 2). Sodium-Potassium-Chloride
Cotransporter (NKCC2, gene SLC12A1) is responsible for
Bartter type I, the inwardly rectiﬁed potassium channel
(ROMK or rectifying outer medullary potassium channel,
gene KCNJ1), for Bartter type II, the chloride channel Kb
(ClCKb, gene CLCNKB;) for Bartter type III, the barttin
(gene BSND) for Bartter type IV [3]. A complete deletion
of CLCNKB gene with additional alterations of the ClCK-A
gene leads to a severe form of Bartter syndrome similar to
Bartter syndrome type IV [4, 5]. A biological phenotype of
Barttersyndromehasalsobeenreportedindiﬀerentdamages
of molecular structures that directly or indirectly aﬀect
sodium reabsorption in the Henle loop: the calcium-sensing2 International Journal of Nephrology
receptor (CaSR, activating mutation L125P) that mainly
leads to hypocalcemia and hypercalciuria, sometimes re-
ferred as type V Bartter syndrome [6], the Chloride channel-
5( C l C 5 )[ 7], and the cystinosin [8]. Gitelman syndrome,
due to the alteration of the SLC12A3 gene that encodes the
Sodium chloride cotransporter in the distal convolution, is
also marked by sodium wasting, hyperreninism, hyperal-
dosteronisme,and hypochloremic alkalosis but diﬀers from
Bartter syndrome by hypomagnesemia and hypocalciuria
[3].Thebasolateralpotassiumchannel(KCNJ10)isthecause
of the EAST syndrome (Epilepsy, Ataxia, Sensorineural deaf-
ness, and Tubulopathy) that also displays a phenotype closer
from Gitelman syndrome than from Bartter syndrome [9].
The chronic use of furosemide that blocks the NKCC2 leads
to an acquired biological phenotype of Bartter syndrome
[10]. Nephrotoxic agents (aminoglycosides, amphotericin
B, and heavy metal intoxication) have also been reported
to be sometime associated with a phenotype of Bartter
syndrome [11–13]. Extrarenal loss of sodium chloride by the
gastrointestinal tract (congenital chloride diarrhea) or by the
skin (cystic ﬁbrosis) may also display a biological phenotype
of Bartter syndrome but these patients that have a normal
renal tubular function diﬀered from true Bartter syndrome
by a very low excretion fraction of sodium [14, 15].
2.1. Urinary Sodium Wasting. Assuming a glomerular ﬁl-
tration rate of 100mL/min and a serum sodium concen-
tration of 140mmol/L, about 20mol/day of sodium are
ﬁltered everyday, equivalent to the amount of 1.2kg of salt.
Under physiological conditions, renal tubules are capable of
reabsorbing 99 to 100% of ﬁltered sodium and water. The
primary consequence of a defect in the Henle loop is a failure
to reabsorb 30% of the ﬁltered sodium. The massive amount
of sodium that is delivered downstream to the end of the
Henle loop exceeds the possibility of compensation by the
distal convoluted tubule and the collecting duct and leads to
urinary sodium wasting [3].
2.2. Urinary Concentration and Dilution Defect. As e c o n d
consequence of the defect of Henle loop is the abolition
of the corticopapillary osmolar gradient that prevents the
ability to concentrate the ﬁnal urine over the plasma
osmolality. In addition, patients display a partial impairment
in diluting urine far below the plasma osmolality while half
of the capacity of diluting urine is due to the anhydrous
reabsorption of sodium chloride in the Henle loop, and the
second half is due to the anhydrous reabsorption of sodium
chloride in the distal convoluted tubule [16].
2.3. Hypercalciuria. Urinary calcium wasting is due to the
abolition of the transtubular potential, the subsequent
inability to passively drive divalent cations through the
intercellular space in the Henle loop (see Figure 2) and the
patent failure of downstream adaptation. The chronic loss
of calcium is frequently responsible for an increased bone
resorption and a decrease of bone mineralization that is
proportional to the level of urine calcium [17]. Calcium
supplementation may prevent these bone alterations.
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Figure 1: Segmentation of sodium reabsorption. Sodium reabsorp-
tion in tubular epithelial cells proceeds along a general two-step
mechanism that includes a/an active extrusion of intracellular
sodium ions by the basolateral sodium pump that is common
to all tubular segments, b/ a passive apical entry of sodium
dissipating the electrochemical gradient generated by the sodium
pump via an exchanger or a cotransporter or a sodium channel
that is speciﬁc to each tubular segment. Brieﬂy, 175L/1.73m2
of plasma roughly containing 20 moles of sodium chloride are
ﬁltered every day by the glomeruli, and 99 to 100% of this
amountisreabsorbedintheconvolutedandstraighttubules(60%),
the thick ascending limb of the Henle loop (30%), the distal
convoluted tubule (7%), the connecting and the collecting duct
(0 to 3%, controlled by aldosterone and angiotensin-2). The thin
descending and ascending limbs of the Henle loop do not display
any capacities to reabsorb sodium. Proximal tubular failure leads
to the Fanconi syndrome where sodium wasting is associated
with numerous solute wasting (potassium, bicarbonates, calcium,
phosphates, glucose, aminoacids). Failure of the large ascending
limb of the Henle loop is responsible for the Bartter syndrome, of
the distal convoluted tubule for the Gitelman syndrome, and of the
collecting duct for type 1 Pseudohypoaldosteronism [3].
3.Secondary BiologicalAdaptations
3.1. Hyperreninism. The extracellular volume is a sodium
salt solution that is closely maintained to a steady-state
osmolality of 300mosmol/Kg. Chronic sodium depletion
subsequently leads to a contraction of the extracellular
volume. Hypotension, failure to thrive, and at the biological
level, either an increased concentration of the total plasma
protides or a high hematocrit are the common signs of
extracellular volume contraction [19, 20]. Chronic hypov-
olemia results in a stimulation of the renin axis and enhances
the production of angiotensin-2 that stimulates the sodium
reabsorption in the principal cell of the collecting duct
(Figure 3)[ 21].
3.2. Hyperaldosteronism. Angiotensin-2 directly increases
the secretion of aldosterone by the granulosa of the adrenal
glands [22]. Aldosterone adds to the stimulation of theInternational Journal of Nephrology 3
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Figure 2: Structures involved in sodium reabsorption in the Henle
loop. The large part of the Henle loop is mainly dedicated to sodium
reabsorption. The system is vectorized and energized by the sodium
pump at the basolateral face of the cell. KCNJ10 (not drawn on
the ﬁgure) is supposed to recycle potassium at the basolateral face
of the cell allowing fueling of the sodium pump in extracellular
potassium. At the apical face, the sodium is cotransported with 1
potassium and 2 chlorides by the NKCC2 cotransporter. The four
sitesoftheNKCC2havetobeoccupiedtogenerateanelectroneutral
transport. As the urinary ﬂuid is 30-fold more concentrated in
sodium than in potassium, potassium ions are recycled in the urine
ﬂuid at the luminal face of the cell through the ROMK (rectiﬁed
outer medullary potassium) channel, in order to provide enough
potassium for a continuous activity of the NKCC2. The 2 chlorides
are reabsorbed at the basolateral face of the cell by the chloride
channels CLCKA and B. Those channels need to be addressed
and clustered at the basolateral membrane by the barttin. The
main regulator of sodium reabsorption in the Henle loop is the
vasopressin(alsoreferredasantidiuretichormone).Theasymmetry
ofchargesinthelumen(excessofpotassium)andintheinterstitium
(excess of chloride) generates a potential according to the 3rd
principle of thermodynamics (Nernst formula). The paracellular
transportofcations(calciumandmagnesiumaswellassodiumand
potassiuminsomeextent)throughtheintercellularspaceisallowed
by special claudins (claudines16 and 19, also referred as paracellins)
and dissipates the transepithelial potential of the Henle loop [2, 3].
sodium reabsorption in the collecting duct and also likely
stimulates those in the distal convoluted tubule [23]. Hyper-
aldosteronism may be dampened, relatively to a high renin
stimulation, by hypokalemia and potassium depletion that
directly interfere with aldosterone secretion in the granulosa
[22].
3.3. Hypokalemia. As in any case of hyperaldosteronism,
the exacerbation of the sodium reabsorption is closely
associated to an exacerbation of the potassium secretion
due to the stimulation of the crossed transport activity of
sodium and potassium by the sodium pump. Consistently,
hyperaldosteronism and urinary potassium wasting improve
when sodium supplementation is increased [24]. Conversely,
hypokalaemia and potassium depletion may improve with
angioconvertase inhibitors, likely through a decrease of pro-
duction of angiotensin-2 and the deactivation of the collect-
ing duct [25]. Accordingly, patients treated with enalapril
had a fall in blood pressure and a decrease in glomerular
ﬁltration rate [25].
3.4. Alkalosis. The mechanism of alkalosis might be ex-
plained by an eﬀect of aldosterone on the expression of
the proton ATPase located in the α-intercalated cell but,
α-intercalated cell does not express the mineralocorticoid
receptor [26, 27]. A second possibility is that the potassium
depletionmightberesponsibleforadenovoexpressionofthe
gastric proton-potassium ATPase (sensitive to omeprazole)
at the luminal face of the principal cell in order to reabsorb a
part of the secreted potassium. For each potassium ion that
is internalized, 1 hydrogen is extruded in the urine by the
proton potassium ATPase, generating alkalosis [18, 28]. This
adaptation that has been fully demonstrated in rat models of
potassium depletion might also apply to humans.
3.5. Complications of Potassium Depletion. Hypokalemic
periodic paralysis and rhabdomyolysis has been reported for
hypokalaemia below 2mmol/L and fully resolved following
the reload of the system with potassium chloride [29, 30].
Prolonged QT interval has been evidenced with hypokalemia
below 2mmol/L, and subsequent aborted sudden cardiac
death may occur [31, 32]. Potassium depletion also induces
coronary microvascular and myocardial defects during exer-
cise in patients with Bartter syndrome [33].
3.6. Polyuria. The mechanism of polyuria in Bartter syn-
drome has to be considered diﬀerently in the antenatal
period and after birth. In the antenatal period, the ﬁnal
urine delivered by a normal fetus is hypoosmolar suggesting
that the water reabsorption in the collecting duct is not
yet matured before birth while the anhydrous reabsorption
of sodium chloride is fully functional in the Henle loop
[34, 35]. In the amniotic ﬂuid, the fetal urine is balanced
with the fetal plasma that circulates in the fetal membranes
(amnion and chorion) [34]. In physiological conditions, the
diﬀerenceoftheosmoticpressurebetweentheamnioticﬂuid
and the fetal plasma strongly favors a water outﬂow from
the amniotic ﬂuid into the capillaries of the fetal membranes
[36]. Indeed, 5 types of aquaporins (AQP-1, -3, -4, -8,
-9) are strongly expressed in the amnion and the chorion
[37]. In fetus with Bartter syndrome, the amniotic ﬂuid is
fed with the fetal urine that is released at the end of the
proximal convoluted tubule and not modiﬁed in the Henle
loop.Intheseconditions,thefetalurinaryosmolalityisequal
to those of the fetal plasma, likely preventing any water
transfer from the amniotic ﬂuid into the fetal plasma and
leading to a polyhydramnios. The concentration of solutes
remainsbalancedintheamnioticﬂuidwhilethetotalprotein
concentration (the solid phase) is diluted [38]. After birth,
the polyuria is supposed to be generated by the addition of
theinability ofthekidneys toconcentratetheﬁnalurine over
the plasma osmolality and the increase of excreted osmoles
due to the urinary sodium and potassium wasting.4 International Journal of Nephrology
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Figure 3: Activation of the principal cell of the collecting duct by aldosterone and angiotensin-2. The collecting duct is a composite structure
made of 3 types of cells: the principal cell that assumes sodium and water reabsorption and potassium secretion, the α-intercalated cell
dedicated to hydrogen secretion, and the β-intercalated cell dedicated to bicarbonate secretion. In the principal cell, the reabsorption of
sodium is vectorized through the epithelial sodium channel at the apical side of the principal cell and the sodium pump at the basolateral
side. Potassium ions are cross-transported against sodium ions by the sodium pump and secreted in the lumen by the ROMK channel that is
the same ROMK channel expressed in the Henle loop. Chronic sodium depletion and the subsequent extracellular volume contraction lead
to an activation of the renin-angiotensin2-aldosterone axis that leads to the enhancement of sodium reabsorption and an exacerbated cross-
secretion of potassium by the principal cell. The subsequent potassium depletion leads to hypokalemia and likely induces the expression
of the gastric proton-potassium pump (inhibited by omeprazole) at the apical face of the principal cell leading to an excessive secretion of
hydrogen and a subsequent alkalosis [18].
3.7. Hyperprostaglandinuria. Hyperprostaglandinuria is not
speciﬁc of Bartter syndrome and has been either reported
in sodium depletion without Bartter syndrome [39, 40]o r
in water deprivation [41–43]. Tissular secretion of PGE2
is stimulated by the vasopressin [44] either secondary to
hypovolemia due to a sodium depletion or hypernatremia.
In the kidney, cyclooxygenase-1 (COX1) is highly expressed
in the collecting duct, and cyclooxygenase-2 (COX2) is
expressed predominantly in the renal medullary interstitial
cells, in the cortical thick ascending limb and in the cells
associated with the macula densa. In addition, prostaglandin
E synthase (PGES1) is highly expressed in the collecting duct
and also detected in the thick ascending limb and the macula
densa [45].
4.Speciﬁcitiesaccordingto
the MolecularDefect.
4.1. SLC12A1 (NKCC2). Mutations of SLC12A1 gene have
been associated with the most typical form of antenatal
Bartter syndrome featuring early onset of polyhydramnios,
neonatal polyuria, and dehydration requiring massive
amount of water and sodium supplementation in the ﬁrst
days of life, detectable nephrocalcinosis on renal ultrasound
within the ﬁrst month, and high plasma level of renin and
secondary hypokalemic alkalosis following the ﬁrst days
of life [46, 47]. A delayed onset in life has also been
exceptionallyreportedincaseswitharesidualfunctionofthe
NKCC2 cotransporter [48].
4.2. ROMK (KCNJ1). Mutations in the KCNJ1 gene display
the same clinical phenotype as described in the NKCC2
section,buttransienthyperkalemiaandacidosisareobserved
during the ﬁrst month of life [46, 47, 49]. Kalemia secondar-
ilydecreasesalongthecourseofthedisease,buthypokalemia
frequently failed to develop in these patients [47, 49]. A
delayed onset in life has also been exceptionally reported in
cases with a residual function of the ROMK channel [50].
4.3. ClCK-b (CLCNKB). Mutations in the CLCNKB gene
give the most variable clinical phenotypes from early poly-
hydramnios and severe neonatal polyuria [46, 47] to classicInternational Journal of Nephrology 5
Bartter syndrome with a delayed diagnosis in childhood and
failure to thrive [51]a n dt ot h ep h e n o t y p eo fG i t e l m a n
syndrome without polyuria [52]. Hypercalciuria may lack in
some patients with CLCNKB mutations [46].
4.4. Barttin (BSND). Barttin mutations are marked by
deafness [53]. Most of the patients have a severe tubular
disease, but a few adults have been recognized on deafness
with a mild renal phenotype [54]. Hypercalciuria may also
lack in a set of patients with BNSD mutations [46].
5. Treatment
Undelayed management of neonates with fully symptomatic
antenatal Bartter syndrome is a necessity. Prenatal diagnosis
relies on the occurrence of polyhydramnios without any
classical cause of polyhydramnios (mainly maternal diabetes
andfetalgastrointestinaltractmalformation).Theanalysisof
sodium, potassium, and chloride concentration relatively to
those of total protein and alphafetoprotein in the amniotic
ﬂuid (the Bartter Index) is a reliable tool to conﬁrm the
diagnosis when familial history is lacking [38].
5.1. Sodium Chloride and Water. According to the phys-
iopathology of the disease, the primary treatment of Bartter
syndrome, at least in the neonatal period and in childhood,
is the supplementation in sodium chloride. Data are scarce
but some reports show that the amounts of sodium chloride
needed to balance the extracellular volume, and prevent
dehydration and hypovolemia to limit the stimulation of
the renin axis, may reach 50mmol/Kg/day in neonates
[46, 55, 56]. Polyuria may occur immediately after birth
prior to any sodium supplementation and requires water
inputs that have sometimes to be rapidly increased up to
500mL/Kg/day within the ﬁrst days of life [55, 56]. Secon-
darily, continuous supplementation with water and sodium
chloride either through a nasogastric tube or a gastrostomy
may be necessary to improve growth in weight and length
during the ﬁrst months or years of life [57, 58]. A free
access to sodium chloride and water when children gain food
autonomy is as much as important that a free access to water
for the children that are aﬀected with a nephrogenic diabetes
insipidus. Intravenous infusions of sodium salt solutions are
necessary to prevent life-threatening dehydration in case of
vomiting or diarrhea.
5.2. Potassium Chloride. Sodium chloride supplementation
should be the best way to preserve children from hypo-
kalemia and potassium depletion through the control of
the extracellular volume and the renin-aldosterone axis.
[59] Nevertheless, in some patients, the amounts of sodium
chloride that would balance the extracellular volume and the
renin system are so elevated that they are not acceptable by
the patient. A potassium-rich diet and potassium chloride
supplementation are subsequently needed.
5.3. Indomethacin. Indometacin has been used either prior
to birth to prevent the recurrence of a polyhydramnios or
after birth to limit the polyuria [60, 61]. In the fetus with
a Bartter syndrome, the amount of urine that is delivered
at the end of the proximal convoluted tubule is directly
proportional to the glomerular ﬁltration rate. Therefore,
the eﬀect of indomethacin in preventing the recurrence
of polyhydramnios following a drain is likely due to its
action on glomerular vasculature, the reduction of the fetal
glomerular ﬁltration rate, and the subsequent reduction
of fetal urine output [62]. After birth, prostaglandins are
paradoxically potent inhibitors of the sodium reabsorption
in the collecting duct through their speciﬁc receptor EP1
and EP2 [45, 63]. In addition, inhibition of prostaglandin
synthesis during fasting in healthy man increases renal
sodium absorption through a possible direct regulation of
the epithelial sodium channels [64]. In the same time,
prostaglandins are likely to be responsible for a decrease of
the expression of aquaporin-2 and the V2 receptor resulting
in a decrease of water permeability in the collecting duct
[65] that is supposed to amplify the polyuria. Therefore, the
beneﬁcial eﬀect of indomethacin on urinary sodium wasting
and polyuria might be better ﬁgured out by the inhibition of
the prostaglandins pathway on tubular structures than by a
mild or a moderate decrease of the glomerular ﬁltration rate
[66,67].However,prescribersmustbeawarethatnecrotizing
enterocolitis and death have been reported following the use
of indomethacin in the neonatal period [55, 58, 68–70].
5.4. Potassium-Sparing Drugs. M a n yd r u g sa r es u s c e p t i b l et o
block the secretion of potassium in the collecting duct and
to prevent potassium depletion. Those that have been used
in Bartter syndrome are modamide, the antagonist of the
Epithelial Sodium Channel, spironolactone, the antagonist
of mineralocorticoid receptor, and angiotensin-converting
enzyme inhibitors. Unfortunately, all these drugs impair the
stimulationofthesodiumreabsorptioninthecollectingduct
and are susceptible to worsen the urinary sodium wasting
and the chronic contraction of the extracellular volume
[25, 71, 72].
6. UnresolvedandNew Questions
6.1. Cysts. The development of renal cysts have been re-
ported in patients with Bartter syndrome, of whom one had
a mutation in the CLCNKB gene [61, 73]. The mechanism
remains unveiled.
6.2. Chronic Renal Failure. Renal ﬁbrosis has been reported
in a series of 12 patients, of whom four had a decreased
glomerular ﬁltration rate. No statistical correlations could
be established between the indomethacin dose and the per-
centage of altered interstitial surface area [74]. By contrast,
signiﬁcant relationships have been evidenced between the
severity of urinary sodium wasting and the level of the
glomerular ﬁltration rate suggesting that the extent of renal
ﬁbrosis might be related to the chronic contraction of
the extracellular volume and hypovolemia. Consistently, the
development of chronic renal failure is a frequent feature in
patients with a barttin mutation in parallel to severe chronic6 International Journal of Nephrology
extracellular dehydration [53, 75]. In addition, chronic
renal failure has also reported in patients who developed
proteinuriaandlesionsoffocalsegmentalglomerulosclerosis
superimposed to a Bartter syndrome [76, 77]. Finally, end
stage renal failure is rare but has been yet reported [78].
6.3.SecondaryDiabetesInsipidus. Hypernatremiawithspon-
taneous diluted urine below 100mosmol/Kg and failure to
concentrate urine over 200mosmol/Kg has been reported
without any mutation in the genes of the V2 receptor and
aquaporine-2 [57]. Diluted ﬁnal urine may be paradoxical
in Bartter syndrome while the Henle loop is a major site
to dilute urine. One should recall that the ﬁrst half of
the distal convolution is also water impermeable while
aquaporine-2 is never coexpressed along with the sodium-
chloride transporter [79] and that the distal convolution
may consequently account for by a nonnegligible part of
the diluting urine capacity [80]. Nevertheless, the failure
of the principal cell of the collecting duct to appropriately
transport water when strongly and continuously activated by
angiotensin-2 and aldosterone remains to be understood.
6.4. Cholelithiasis. A case of cholelithiasis has been reported
recently and attributed to alkalosis and dehydration that
favour precipitation of calcium carbonate in biliary ducts
[81].
7. Conclusion
In conclusion, renal physiology allows a rational approach
to understand the biological features of Bartter syndrome
and supports sodium chloride supplementation as the most
appropriate treatment to control both the extracellular vol-
umeandthepotassiumdepletion.Onabasicpointofview,it
is noteworthy that the preservation of the sodium pool (and
the balance of the extracellular volume) is a higher priority
of the system than the protection against the potassium
depletion, itself a priority upon the hydrogen balance.
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